Compare TECX & ASPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TECX | ASPI |
|---|---|---|
| Founded | 2019 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Major Chemicals |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 618.9M | 507.5M |
| IPO Year | 2018 | 2022 |
| Metric | TECX | ASPI |
|---|---|---|
| Price | $28.61 | $3.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $75.20 | $12.00 |
| AVG Volume (30 Days) | 197.5K | ★ 3.4M |
| Earning Date | 05-07-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.70 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $23,849,000.00 |
| Revenue This Year | N/A | $68.41 |
| Revenue Next Year | N/A | $126.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 475.48 |
| 52 Week Low | $14.39 | $3.30 |
| 52 Week High | $39.53 | $14.49 |
| Indicator | TECX | ASPI |
|---|---|---|
| Relative Strength Index (RSI) | 39.61 | 31.90 |
| Support Level | $27.53 | N/A |
| Resistance Level | $31.39 | $4.45 |
| Average True Range (ATR) | 2.27 | 0.23 |
| MACD | -0.57 | -0.07 |
| Stochastic Oscillator | 5.14 | 8.09 |
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
ASP Isotopes Inc is a materials company focused on producing and commercializing enriched isotopes for the nuclear medicine, healthcare, green energy, and quantum computing industries. Currently, the company has three operating segments: (i) nuclear fuels, (ii) specialist isotopes and related services, and (iii) construction services. Using proprietary technology-the Aerodynamic Separation Process (ASP)-the company enriches isotopes in South Africa, targeting high-value, low-volume markets to reduce reliance on foreign supply chains. Geographically, the company operates in South Africa, Hong Kong and United States generating key revenue from the Hong Kong region.